TECON BIOLOGY CO.LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.63 CNY | -1.29% |
|
+5.24% | -13.00% |
| 05-10 | Tecon Biology's April Pig Sales Revenue Fall 9% | MT |
| 04-29 | TECON BIOLOGY Co.LTD Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 13,598 | 11,386 | 11,517 | 11,255 | 11,973 | 10,417 | - | - |
| Enterprise Value (EV) 1 | 13,598 | 15,808 | 14,888 | 15,009 | 15,185 | 14,781 | 14,925 | 10,417 |
| P/E ratio | 21.3 x | 6.62 x | -17.3 x | 37.8 x | -8.68 x | 18.8 x | 7.93 x | 9.91 x |
| Yield | - | 4.34% | - | 2.65% | - | 0.88% | 2.57% | - |
| Capitalization / Revenue | 1.82 x | 0.95 x | 0.73 x | 0.67 x | 0.63 x | 0.49 x | 0.43 x | 0.41 x |
| EV / Revenue | 1.82 x | 1.32 x | 0.95 x | 0.9 x | 0.8 x | 0.69 x | 0.62 x | 0.41 x |
| EV / EBITDA | 14.7 x | 6.88 x | 103 x | 15 x | -24 x | 10.2 x | 5.63 x | 4.6 x |
| EV / FCF | - | - | - | -14 x | 20.2 x | -94.8 x | 19.6 x | - |
| FCF Yield | - | - | - | -7.16% | 4.95% | -1.06% | 5.1% | - |
| Price to Book | 2.97 x | 1.83 x | 2.03 x | 1.42 x | - | 1.55 x | 1.24 x | 1.25 x |
| Nbr of stocks (in thousands) | 1,063,994 | 1,075,135 | 1,076,337 | 1,354,339 | 1,365,252 | 1,365,252 | - | - |
| Reference price 2 | 12.78 | 10.59 | 10.70 | 8.310 | 8.770 | 7.630 | 7.630 | 7.630 |
| Announcement Date | 20-02-25 | 21-04-22 | 22-04-26 | 23-04-28 | 24-04-28 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 7,476 | 11,987 | 15,744 | 16,732 | 19,026 | 21,320 | 23,956 | 25,639 |
| EBITDA 1 | 924.8 | 2,297 | 144.3 | 1,002 | -632 | 1,454 | 2,649 | 2,265 |
| EBIT 1 | 590.7 | 1,808 | -599.9 | 276.6 | -1,446 | 606 | 1,584 | 1,179 |
| Operating Margin | 7.9% | 15.08% | -3.81% | 1.65% | -7.6% | 2.84% | 6.61% | 4.6% |
| Earnings before Tax (EBT) 1 | 589.9 | 1,808 | -646.5 | 235.8 | -1,493 | 563.8 | 1,496 | 1,139 |
| Net income 1 | 644.5 | 1,720 | -686 | 301.5 | -1,363 | 555.6 | 1,308 | 1,054 |
| Net margin | 8.62% | 14.35% | -4.36% | 1.8% | -7.17% | 2.61% | 5.46% | 4.11% |
| EPS 2 | 0.6000 | 1.600 | -0.6200 | 0.2200 | -1.010 | 0.4050 | 0.9618 | 0.7700 |
| Free Cash Flow 1 | - | - | - | -1,074 | 751.4 | -156 | 761 | - |
| FCF margin | - | - | - | -6.42% | 3.95% | -0.73% | 3.18% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 28.72% | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | 58.18% | - |
| Dividend per Share 2 | - | 0.4600 | - | 0.2200 | - | 0.0673 | 0.1958 | - |
| Announcement Date | 20-02-25 | 21-04-22 | 22-04-26 | 23-04-28 | 24-04-28 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 4,422 | 3,371 | 3,754 | 3,212 | 4,364 | 4,508 | - |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 1.925 x | 23.36 x | 3.746 x | -5.082 x | 3.001 x | 1.702 x | - |
| Free Cash Flow 1 | - | - | - | -1,074 | 751 | -156 | 761 | - |
| ROE (net income / shareholders' equity) | 16.8% | 31.9% | -11.7% | 4.07% | -19.2% | 7.44% | 14.5% | 10.6% |
| ROA (Net income/ Total Assets) | - | 12.8% | - | - | - | 3.15% | 7.63% | 5.68% |
| Assets 1 | - | 13,442 | - | - | - | 17,621 | 17,135 | 18,553 |
| Book Value Per Share 2 | 4.310 | 5.790 | 5.280 | 5.870 | - | 4.910 | 6.160 | 6.090 |
| Cash Flow per Share 2 | 0.2900 | -0.5600 | 1.130 | 0.2400 | 1.280 | 1.980 | 1.130 | -0.2200 |
| Capex 1 | 1,350 | 930 | 1,749 | 1,402 | 1,000 | 774 | 904 | 498 |
| Capex / Sales | 18.06% | 7.76% | 11.11% | 8.38% | 5.26% | 3.63% | 3.77% | 1.94% |
| Announcement Date | 20-02-25 | 21-04-22 | 22-04-26 | 23-04-28 | 24-04-28 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
7.63
CNY
Average target price
8.548
CNY
Spread / Average Target
+12.02%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -13.00% | 1.44B | |
| -2.39% | 275B | |
| -1.70% | 95.5B | |
| -2.00% | 44.01B | |
| +9.84% | 41.41B | |
| +1.40% | 41.13B | |
| +8.54% | 39.91B | |
| -12.79% | 31.14B | |
| -4.77% | 29.23B | |
| +14.15% | 25.26B |
- Stock Market
- Equities
- 002100 Stock
- Financials TECON BIOLOGY Co.LTD
